Our 5-minute online survey conducted in the fall of 2020 sought to gain clarity around remote detailing. This study was conducted with 339 Canadian physicians who are members of the MD Analytics healthcare panel and the results provide actionable recommendations on how to form a more ‘ideal’ pharma remote detail.
We asked 180 Canadian physicians of which pharmaceutical company they have the highest opinion. Overall, there was no clear winner. However, when asked by disease areas, some leaders emerge.
Top companies seen as leader in…(% ranked 1-3)
- Neurology: Novartis (46%); Roche (38%); Lilly (37%)
- Cardiovascular Disease: Merck (51%); AstraZeneca (43%); Pfizer (43%)
- Respiratory: GSK (69%); AstraZeneca (67%); Boehringer Ingelheim (56%)
- Gastroenterology: Merk (67%); Pfizer (61%); Janssen (56%)
- Diabetes: Lilly (50%); Novo Nordisk (40%); AstraZeneca (37%)
- Psoriasis: Leo (65%); Galderma (57%); Janssen (24%)
Past Quick Polls
The COVID-19 crisis has significantly impacted physicians’ practices; but how and to what extent? Physicians have been managing significant workloads, while learning on the fly how to navigate and setup virtual meetings. Maintaining high levels of patient care while minimizing in-person interactions has also been challenging.
Strong online advertising and messaging are key to maximizing impact of any marketing campaign. With recent restrictions on in-person interactions, online advertising and messaging play an even greater role in reaching physicians. Our findings from a survey of n=227 Canadian physicians show that 82% of Canadian physicians have increased their use of online platforms as a result of COVID-19, 48% significantly so.
Physicians recognize that new medications often can be quite valuable for their patients and are eager to add them to their armamentarium. However, they do not always end up prescribing these new medications as much as they initially plan or as early as they would like. There are many reasons that can explain this discrepancy.
Past Quick Polls
Physicians recognize that new medications often can be quite valuable for their patients and are eager to add them to their armamentarium. However, they do not always...